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ORIGINAL ARTICLE
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BACKGROUND TcP21 is a ubiquitous secreted protein of Trypanosoma cruzi and its recombinant form (rP21) promotes parasite 
cell invasion and acts as a phagocytosis inducer by activating actin polymerisation in the host cell.
OBJECTIVE Our goal was to evaluate if the additional supplementation of rP21 during a prime/boost/challenge scheme with T. 
cruzi TCC attenuated parasites could modify the well-known protective behavior conferred by these parasites.
METHODS The humoral immune response was evaluated through the assessment of total anti-T. cruzi antibodies as well as IgG 
subtypes. IFN-γ, TNF-α and IL-10 were measured in supernatants of splenic cells stimulated with total parasite homogenate or rP21.
FINDINGS Our results demonstrated that, when comparing TCC+rP21 vs. TCC vaccinated animals, the levels of IFN-γ were 
significantly higher in the former group, while the levels of IL-10 and TNF-α were significantly lower. Further, the measurement 
of parasite load after lethal challenge showed an exacerbated infection and parasite load in heart and skeletal muscle after pre-
treatment with rP21, suggesting the important role of this protein during parasite natural invasion process.
MAIN CONCLUSION Our results demonstrated that rP21 may have adjuvant capacity able to modify the cytokine immune profile 
elicited by attenuated parasites.
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For many parasitic diseases, vaccines had the poten-
tial to overcome the lack of an efficient chemotherapeu-
tic treatment ― or its limited efficacy ― and its associ-
ated side effects. There has been a great progress related 
to vaccine development for several parasitic diseases but 
for Chagas disease, as well as for other neglected diseas-
es, the progress has not been so encouraging. However, 
in the past decade an increasing number of evidence sug-
gests that a vaccine against Trypanosoma cruzi would 
be feasible and reasonable in terms of economic values. 
Several immunoprophylactic as well as immunothera-
peutic attempts have been made in order to prevent T. 
cruzi establishment and persistence in the host. Most 
assessed protocols included heterologous, prime-boost 
immunisation schemes based on the combination of 
DNA vaccines and recombinant proteins.(1) These were 
delivered or supplemented in various forms, including 
immune response enhancers such as adenoviruses,(2) at-
tenuated Salmonella sp,(3) Modified Vaccinia Ankara(4) 
and most recently, nanoparticles.(5) Also, the use of new 
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generation adjuvants based on saponin(6) or Toll Like 
Receptors (TLR) agonists(7) for instance has gained re-
awakened attention. In addition, the generation of ge-
netically modified T. cruzi mutant strains and their use 
as experimental immunogens has shown a significant 
protection against lethal infection,(8,9) and presumably no 
persistence in the host, rendering this alternative worth 
to keep working on.(10,11) On the other hand, several para-
site antigens, such us proteins from the trans-sialidase 
(TS) superfamily, or proteins Tc24 and Tc52 for instance, 
have also been tested in animal models.(12)
Among T. cruzi proteins, there is one that particu-
larly gained our attention. P21 is a key protein secreted 
by all developmental stages of T. cruzi. It is mainly in-
volved in cell invasion and modulation of the host im-
mune response, although its role during parasite infec-
tion is not fully elucidated yet. It has been demonstrated 
that recombinant P21 (rP21), produced by heterologous 
expression, promotes T. cruzi cell invasion by confining 
to the chemokine receptor CXCR4 expressed in macro-
phages and acts as a phagocytosis inducer by activating 
actin polymerisation in the host cell.(13,14) It has also been 
shown that rP21 participates in macrophages activation 
by increasing the production of myeloperoxidase, there-
fore recruiting immune cells such as lymphocytes and 
neutrophils. Even more, a decrease in blood vessel for-
mation in the presence of rP21 has been observed lead-
ing to the hypothesis that its anti-angiogenic effect may 
be related to vascular abnormalities and to focal isch-
emia observed in chronic chagasic cardiomyopathy.(15,16)
Cecilia Pérez Brandán et al.2|7
In our experience and from others as well, a subpatent 
infection with naturally or genetically modified attenuat-
ed parasites is enough to confer strong protection against a 
subsequent infection.(10,17,18) Hence, if rP21 is described as 
a determinant protein favoring parasite cell invasion and 
permanence in the host, we could speculate that the ad-
ditional supplementation of rP21 during the immunisation 
process with the attenuated parasites would promote the 
continuity of the parasites in the host for a longer period 
of time, thus giving additional time for the development 
of a prophylactic immune response able to avoid a second 
parasite establishment. On the other hand, we would be 
also favoring the recruitment of immune cells in a larger 
extent being able to improve the protective immune re-
sponse conferred by the attenuated parasites.
MATERIALS AND METHODS
Ethics statement - All animal protocols adhered to the 
National Institutes of Health (NIH) ‘‘Guide for the care 
and use of laboratory animals’’ and were approved by the 
School of Health Sciences and by the Ethical Committee 
of the National University of Salta, Argentina (Nº 311/18).
Protein and parasites preparation - For the immuni-
sation assays, recombinant T. cruzi protein rP21 was 
used as well as metacyclic trypomastigotes from the 
T. cruzi naturally attenuated TCC strain. rP21 was ob-
tained from bacteria culture as previously described.(19) 
Epimastigotes were grown at 28ºC in liver digested neu-
tralised tryptose medium (LDNT), supplemented with 
10% foetal bovine serum (FBS) until they reached log-
phase. Metacyclics trypomastigotes were then obtained 
by epimastigotes differentiation under chemically de-
fined conditions (TAU 3AAG medium: 190 mM NaCl, 
17 mM KCl, 2 mM CaCl2, 8 mM phosphate buffer, 2 
mM MgCl2, pH 6.8, supplemented with 0.035% NaH-
CO3, 10 mM l-proline, 50 mM sodium glutamate, 2 mM 
l-aspartate y 10 mM glucose) and harvesting differenti-
ated parasites after 10 days. Complement resistant forms 
were purified by incubating differentiated parasites with 
normal human non decomplemented serum at 37ºC dur-
ing 5 h. Purified parasites were then washed with PBS 
1X twice, quantified under light microscopy and further 
used to inoculate experimental animals.
Mice - Six week old male C57BL/6 mice were used. 
The animals were obtained from the animal facility core 
of the School of Health Sciences of the National Univer-
sity of Salta, Argentina.
Immunisation protocol - Five mice per group (n = 5) 
were used throughout this study. Mice were maintained 
under standard conditions on 12 h light-dark cycle in a 
temperature controlled setting (25ºC) with food and wa-
ter ad libitum. Mice under anesthesia were immunised in-
tramuscularly (IM) with two doses, delivered at 4-week 
intervals, of 105 metacyclic attenuated TCC parasites in 
combination with 20 µg of rP21. Control groups, includ-
ing rP21 and attenuated parasites separately, as well as 
PBS-5% saponin (control -) were included all throughout 
the experiments. All the formulations were emulsified in 
PBS-5% saponin as a vehicle (Cat. Nº SAE0073-Sigma-
Aldrich) in 50 µL final volume per mouse. Before chal-
lenge, blood was collected from all mice in order to col-
lect sera samples for IgGs determination. Also, two mice 
from each group were sacrificed by CO2 exposure for 
spleen removal and further splenocytes isolation and cy-
tokines measurements. The whole experimental proto-
col was repeated twice from immunisation to challenge.
Specific antibody determinations - Total IgG anti-
bodies and IgG subtypes against T. cruzi and rP21were 
measured by the enzyme-linked immunosorbent assay 
(ELISA) using T. cruzi epimastigote homogenate (EH) 
by seeding 1 µg EH/100µl-Coating Buffer/well, and 
0.5 µg rP21/100 µL-Coating Buffer/well, as antigens. 
To identify total antibodies and subtypes, plates were 
blocked with PBS-5% non-fat dry milk, and then incu-
bated with sera samples (1:100 dilution, 100-µL/well) for 
1 h. After washing three times, biotin-conjugated goat 
anti-mouse IgG (Cat. Nº B6649 - Sigma-Aldrich), IgG1 
(Cat. Nº 550331 BD Biosciencies) and IgG2a/c (Cat. Nº 
550332 - BD Biosciencies) in a 1:6000 dilution were 
added (100-µL/well). After 1 h incubation, the plate was 
washed three times with PBS and streptavidin-horse-
radish peroxidase conjugate was added (Cat. Nº 550946 
- BD Biosciencies) and let for 1 h at 37ºC. Colour was 
developed with TMB Substrate Reagent Set (Cat. Nº 
555214-BD Biosciencies) and monitored at 450 nm using 
a Tecan Infinite Pro microplate reader.
Cytokine response - Spleens were removed from eu-
thanised immunised mice, macerated on a sterile mesh, 
and cells were resuspended in RPMI 1640 medium (Cat. 
Nº R7755 - Sigma-Aldrich). Following centrifugation at 
160 × g for 10 min at 4ºC, the cells were resuspended in 
a lysis solution (0.17 M Tris pH 7.2, 0.16 M NH4Cl) to 
remove erythrocytes. The remaining splenocytes were 
washed three times with RPMI and resuspended in RPMI 
supplemented with 20 mM glutamine, 10% NaHCO3 and 
10% FBS. Viability of cells was assessed by Trypan blue 
exclusion and cell number was determined in a Neubauer 
chamber. Splenocytes (106cells/well, in triplicate) were 
cultured for 48 h at 37ºC and 5% CO2, with or without 
stimulation with 25 µg/mL rP21, 25 µg/mL of T. cruzi 
epimastigote homogenate (EH) or 50 µg/mL of phyto-
haemagglutinin (PHA). Cell culture medium was then 
collected to measure the released of IL-10, TNF-α and 
IFN-γ by ELISA according to the instructions of the 
manufacturer (optEIA enzyme-linked immunosorbent 
assay kits, BD-Biosciencies, San Diego, CA).
Challenge infection in mice and parasitaemia - To 
evaluate the response to T. cruzi upon immunisation, mice 
from each group were challenged with T. cruzi Tulahuen 
strain (500 blood trypomastigotes/mouse, intraperitone-
ally). Mortality was twice a week until 30 days post chal-
lenge. Parasitaemia was carried out according to previ-
ously standardised methods. Briefly, blood (10 µL) was 
drawn from the tail tip of mice under slight anesthesia, 
and the number of parasites per 100 fields was recorded 
from fresh blood mounts under bright-field microscope.
Parasite DNA detection - Thirty days after challenge 
mice were sacrificed by CO2 exposure to remove target 
organs. Total DNA from skeletal muscle and heart tissue 
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(50 mg) was isolated using the ADN-Puriprep Highway 
nucleic acid kit (Cat. Nº K1205-250; InbioHighway), ac-
cording to instructions provided by the manufacturer. 
Total DNA (10 ng per sample) was used as template, 
and real-time polymerase chain reaction (PCR) per-
formed on a LineGene 9640 Sequence Detection System 
(BIOER) with Eva Green Supermix (Cat. Nº 92005; Bio-
line) and Tc18S rDNA-specific oligonucleotides (SAT_F 
5’GCAGTCGGCKGATCGTTTTCG-3’ and SAT_R 
5’TTCAGRGTTGTTTGGTGTCCAGTG-3’). Data was 
normalised to murine TNF-α (TNF_F 5’-TCCCTCT-
CATCAGTTCTATGGCCCA-3’ and TNF_R 5’CAG-
CAAGCATCTATGCACTTAGACCCC-3’).(20)
Statistical analysis - Statistical analysis was per-
formed using the software GraphPad Prism V5.00. Con-
tinuous variables, such as antibody levels and parasite 
concentrations in blood samples, were analysed with the 
two-tailed Wilcoxon signed-rank test for time course 
plots and with the Mann-Whitney or Kruskal-Wallis 
test for single-day measurements with Dunn’s Multiple 
Comparison Test. Values are expressed as mean with 
standard errors of the mean (SEM) from at least two in-
dependent experiments, with three lectures per sample 
in each case. Differences between two groups consid-
ered significant are denoted as *p ˂ 0.05, **p ˂ 0.01, 
***p ˂ 0.001 or ns no significant.
RESULTS AND DISCUSSION
A few years ago we described a novel T. cruzi protein, 
named P21. We know that rP21 promotes T. cruzi cell in-
vasion,(13) therefore invading parasites could freely mul-
tiply inside the host cell and invade other cells. Besides, 
rP21 could also be acting as a phagocytosis inducer by 
activating actin polymerisation in the host cell (14) hence, 
in this scenario, parasites could be confined within the 
invaded cell due to this phenomenon. Consequently, and 
with these ideas in mind, we wonder what would be the 
role of rP21 in a prime-boost scheme based on highly 
attenuated parasites formulated with rP21, followed by a 
lethal challenge with virulent T. cruzi parasites.
Anti-rP21 specific humoral response is abrogated un-
der the presence of attenuated parasites - As a first in-
stance we focused on determining the levels of total IgGs 
antibodies in sera from immunised animals. For this, mice 
were injected with two doses of TCC+rP21 emulsified in 
PBS-5% saponin with the corresponding control groups. 
Four weeks after the last immunisation, measurement of 
anti-rP21 specific antibody levels indicated that mice re-
ceiving a formulation based on TCC+rP21 were unable to 
maintain the levels of anti-rP21 IgGs elicited by the ad-
ministration of rP21 alone (Fig. 1A). When total IgG lev-
els were measured against a whole T. cruzi homogenate, 
the antibody response induced by the attenuated parasites 
Fig. 1: antibody response in immunised animals. Groups of mice (n = 5 per group) were immunised with TCC + rP21, TCC, rP21 and as a nega-
tive control, PBS- saponin 5% , which is the vehicle in which all the formulations were resuspended. Four weeks after the last immunisation 
blood was collected and the levels of total anti-rP21 (A) and anti-Trypanosoma cruzi IgGs (B) were measured in serum samples. Total anti-rP21 
IgG1/IgG2c (C) and anti-T. cruzi IgG1/IgG2c (D) in serum samples was also measured. Data are presented as mean ± SEM. *, *** stand for p ˂ 
0.05 and p ˂ 0.001 respectively, ns for no significant.
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is maintained despite the addition of rP21 (Fig. 1B) indi-
cating that at least at this level the humoral total anti T. 
cruzi response is not affected.
We could speculate that the lack of detection of anti-
rP21 specific antibodies in the TCC+rP21 group could 
be attributed to the endogenous production of P21 by the 
immunising parasites and further sequester of these an-
ti-P21specific antibodies. Another possible explanation 
for the observed results could be related to the presence 
of a highly variable plethora of antigens when attenu-
ated parasites are introduced. In this situation the addi-
tion of exogenous rP21 could be irrelevant, and lead to 
the generation of antibodies limited to more competitive 
antigens exposed by parasites.
Total T. cruzi and rP21 specific IgG1 and IgG2c anti-
body levels were measured to estimate the elicited T cell 
profile in immunised animals. TCC immunised animals 
are characterised for presenting a Th2 response based 
mainly in the production of T. cruzi specific IgG1 anti-
bodies. In the case in which TCC parasites were formu-
lated with rP21 (TCC+rP21) the response is maintained 
invariable. Neither anti-rP21 IgG1 nor IgG2c were de-
tected in TCC+rP21 immunised animals (Fig. 1C). It has 
been shown that several T. cruzi recombinant proteins 
are able to generated Th1-driven antibodies in vacci-
nated mice;(21,22,23) however, elevated levels of anti-rP21 
IgG1 were detected in rP21 primed animals indicating 
that a Th1 bias profile for a T. cruzi recombinant pro-
tein is not always the rule. The Th2 profile found in 
TCC+rP21 immunised animals, with a predominance 
of anti-T. cruzi IgG1 antibodies and a lower proportion 
of anti-T. cruzi IgG2c antibodies, was similar to the one 
obtained for TCC primed animals, indicating that the 
addition of rP21 did not alter this profile (Fig. 1D). Thus, 
these results allow us to conclude that rP21 does not have 
the potential to modify the antibody profile triggered by 
TCC attenuated parasites. Still, we have evidenced that 
modulation of host immune response during TCC atten-
uated infection is possible. We have previously shown 
that administration of an eukaryotic expression plasmid 
encoding for murine IFN-γ could have beneficial effects 
such us increasing host specific antibody production in 
response to T. cruzi attenuated infection.(24)
Parasite load in peripheral blood and target organs 
after virulent challenge is not reduced by the presence of 
rP21 - The naturally attenuated TCC strain is well known 
for conferring strong protection against a later virulent 
infection. To evaluate the possible adjuvant capacity of 
rP21, all immunised mice were challenge with a lethal 
dose of T. cruzi virulent parasites, from Tulahuen strain 
(Tul), four weeks after the last immunisation. Survival af-
ter challenge was controlled twice a week (Fig. 2A), and 
showed that control groups, inoculated with PBS-5% sa-
ponin or rP21, died between 20 and 30 days after virulent 
infection, whereas mice immunised with a live TCC-con-
taining formulation, were able to resist the virulent infec-
tion. Parasitaemia was recorded twice a week until mice 
from control group succumbed to dead. Animals that 
were immunised with the formula TCC+rP21 presented 
a similar parasitaemia to those only immunised with at-
tenuated parasites (Fig. 2B) showing no significant dif-
ferences at this level. When analysing the parasite load in 
heart and skeletal muscle, the parasite burden of TCC and 
TCC+rP21 groups, remained below the levels detected for 
control groups. Surprisingly, rP21-immunised animals 
presented an elevated T. cruzi parasite load in these or-
gans (Fig. 2C-D). These results could be attributed to the 
Fig. 2: parasite burden in animals immunised with rP21 formulations after lethal challenge. Immunised mice as well as control group were 
infected with a lethal dose of Trypanosoma cruzi trypomastigotes of the Tulahuen strain of T. cruzi four weeks after the last immunisation. 
Survival was recorded twice a week until day 30 (A). Parasitaemia (B) was recorded twice a week until control group died and cardiac (C) and 
skeletal muscle parasite burden (D) was measured at the end of this period. *: p ˂ 0.05; **: p ˂ 0.01; ***: p ˂ 0.001 or ns no significant.
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fact that some rP21 protein residues could still be avail-
able in the host during the challenge, favoring virulent 
parasites to invade cells and multiple in the host. In the 
same way, a similar effect could also have happened in the 
TCC-rP21 group; however, in this case we speculate that 
the presence of TCC could counter this. We have previ-
ously shown through in vitro infection assays that when 
the protein is added at the same time as the parasites, a 
significant increase in host cell invasion is observed.(13) 
Then, we could speculate that something similar could be 
taking place in relation to the parasite load found in blood, 
heart and muscle of rP21 immunised/challenged mice. In 
this case, rP21 would be involved in favoring parasite in-
vasion, rather than acting as an antigen for triggering a 
humoral response. The effect of combining rP21 together 
with attenuated parasites (TCC+rP21) did not translate in 
an improved protection compared to the one conferred by 
immunisation with attenuated parasites alone. We could 
determine that the capacity of rP21 to stimulate cell inva-
sion is higher than its capacity to trigger a robust immune 
response capable of protecting against a virulent chal-
lenge as observed by the lack of protection in the immuni-
sation and challenge experiments.
The cytokine profile evoked by attenuated infection 
was modified by rP21 addition - Over the years, an im-
portant piece of evidence has been collected indicating 
that cytokines play key roles in the control of T. cruzi 
acute infection, being IFN-γ, IL-10 and TNF-α among 
the main cytokines involved.(25) Further analysis of cy-
tokines production in splenocytes from immunised ani-
mals showed that after stimulation with rP21 the levels 
of the analysed cytokines diminished significantly in the 
group of mice immunised with the formula TCC+rP21 
in comparison with the TCC-group (Fig. 3A-C). When 
stimulated with total T. cruzi lysate a similar pattern 
was observed (Fig. 3D-F), even more, in this case, an 
increased in the IFN-γ levels of animals immunised 
with TCC+rP21 was evidenced (Fig. 3D). These data 
suggested that saponin-emulsified rP21, when combined 
with attenuated parasites, is capable of increasing the 
levels of IFN-g upon stimulus with pathogen’ antigens. 
Initial IFN-γ production is known to occur early during 
the course of T. cruzi infection and may be important 
in the development of resistance, being Natural Killer 
cells the major responsible for its secretion. As a mat-
ter of fact, IFN-γ activation during the acute phase of T. 
cruzi infection promotes macrophage activation and re-
active oxygen species production, and as a consequence, 
this higher expression leads to the inhibition of parasite 
replication.(26) Indeed recent studies suggests that IFN-
g could avoid tolerogenic circuits and reduce parasite 
burden in heart and skeletal muscle(27,28) and thus favor 
parasite control in the first steps of infection. Because 
of these reasons, an up-regulation of IFN-g expression 
in immunised mice may represent a valuable modula-
tion gained by rP21 supplementation. Still, at the level 
herein analysed, the increased in the IFN-g production 
by splenocytes of TCC+rP21 immunised animals failed 
to promote a better control of parasite replication af-
ter challenge. On the other hand, the presence of rP21 
diminished the production of TNF-α elicited by the 
immunisation with attenuated parasites alone, when 
stimulated with whole parasite homogenate (Fig. 3E-F). 
High level of TNF-α expression is required for nitric 
oxide production by the activated macrophages and for 
achieving parasite early restrain during the first stages 
of infection. In our experimental approach, the minor 
production of this cytokines displayed by TCC+rP21 im-
munised animals, may be seen as an advantage gained 
by the adjuvant addition, since parasite control was 
achieved through an IFN-γ-dependent response, avoid-
ing a possible detrimental high expression of TNF-α. 
There are several works proposing that IL-10 production 
by T cells favors T. cruzi control and prevents the devel-
opment of a pathologic immune response.(29,30) Accord-
ing to our results, IL-10 seems no to play a fundamental 
role in controlling parasite replication since the parasite 
burden was similar in TCC and TCC+rP21 immunised/
challenge animals. These data strongly suggest a poten-
tial differential modulation of cytokine production by 
rP21 during the course of infection of attenuated para-
sites. However, this modulation does not alter or modify 
the final outcome product of the vaccination.
In summary we described for the first time, the use 
of a T. cruzi recombinant protein as a possible modulator 
during T. cruzi attenuated immunisation. We are allowed 
to conclude that rP21 possess adjuvant capacity able to 
modify the cytokine immune profile elicited by infection 
with attenuated parasites. However, pre-treatment with 
saponin emulsified-rP21 could lead to exacerbate infec-
tion and parasite load in target organs, suggesting the im-
portant role that P21 has over the natural invasion process 
but also pointing out the risks that the administration of 
this component may have over a second proximal infec-
tion. These conclusions may have significant relevance in 
Fig. 3: cytokines production by splenocytes of immunised animals. 
As before, groups of mice (n = 5 per group) were immunised with 
TCC+rP21, TCC, rP21 and as a negative control, PBS-saponin 5%, 
which is the vehicle in which all the formulations were resuspended. 
Four weeks after the last immunisation, two mice were sacrificed, 
spleens removed and splenocytes collected and stimulated with rP21 
or total Trypanosoma cruzi lysate (TcTL) to measure by enzyme-
linked immunosorbent assay (ELISA), the specific cytokines secre-
tion in the culture medium.
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prophylactic and therapeutic strategies for vaccine devel-
opment against Chagas disease. What is more, the obser-
vations made on T. cruzi P21 as an adjuvant component, 
could be valuable in the future design of immunisation 
strategies intended for the control of animal reservoirs.
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